论文部分内容阅读
目的研究DNA拓扑异构酶Ⅱα(Topo-Ⅱα)、增殖细胞核抗原(PCNA)在中枢神经系统星形细胞瘤中的表达,并探讨其与肿瘤恶性程度及预后的关系。方法应用SABC免疫组化技术,检测32例星形细胞瘤ToPo-Ⅱα、PCNA的表达,并针对其与恶性程度及预后生存状况的关系比较进行统计学分析。结果星形细胞瘤Topo-Ⅱα、PCNA的表达在低度恶性组与高度恶性组之间的差异有统计学意义(P<0.01);Log-rank检验及Kaplan-Meier生存曲线分析显示,Topo-Ⅱα、PCNA的表达强度与星形细胞瘤的预后生存时间呈显著的负相关性,Topo-Ⅱα、PCNA的表达水平反映了星形细胞瘤患者的预后情况。结论Topo-Ⅱα、PCNA在中枢神经系统星形细胞瘤中的表达与其恶性程度相关,与患者的预后生存相关。联合检测二者的表达水平对判断肿瘤的恶性程度有一定的参考意义,同时,这两个因子可作为判断与预测星形细胞瘤患者预后的重要指标。
Objective To study the expression of Topo-Ⅱα and proliferating cell nuclear antigen (PCNA) in central nervous system astrocytoma (TCC), and to explore its relationship with malignancy and prognosis of tumor. Methods To detect the expression of ToPo-Ⅱα and PCNA in 32 cases of astrocytomas by SABC immunohistochemical technique and to analyze the relationship between the expression of ToPo-Ⅱα and PCNA with its malignancy and prognosis. Results The expression of Topo-Ⅱα and PCNA in astrocytomas was significantly different between the low-grade group and the high-grade group (P <0.01). Log-rank test and Kaplan-Meier survival curve showed that Topo- Ⅱα, PCNA expression intensity and astrocytoma prognosis survival time was significantly negatively correlated, Topo-Ⅱα, PCNA expression level reflects the prognosis of patients with astrocytoma. Conclusion The expression of Topo-Ⅱα and PCNA in central nervous system astrocytoma is related to the degree of malignancy and prognosis of patients. The combined detection of the two levels of expression of the degree of malignancy of the tumor has a certain reference value, at the same time, these two factors can be used as a judge and prognosis of astrocytoma prognosis of an important indicator.